Non-osteogenic muscle hypertrophy in children with McArdle disease

I. Rodríguez-Gómez 1,2 · A. Santalla 2,3 · J. Díez-Bermejo 4 · D. Munguía-Izquierdo 2,3 · L. M. Alegre 1,2 · G. Nogales-Gadea 5,6 · J. Arenas 4,6 · M. A. Martín 4,6 · A. Lucía 2,7 · I. Ara 1,2

Received: 24 January 2018 / Revised: 28 February 2018 / Accepted: 5 March 2018

Abstract

Introduction McArdle disease is an inborn disorder of muscle glycogen metabolism that produces exercise intolerance, and has been recently associated with low values of lean mass (LM) and bone mineral content (BMC) and density (BMD) in affected adults. Here we aimed to study whether this bone health problem begins in childhood.

Methods Forty children and adolescents were evaluated: 10 McArdle disease and 30 control children (mean age of both groups, 13 ± 2y). Body composition was evaluated by dual-energy X-ray absorptiometry and creatine kinase (CK) levels were determined in the patients as an estimate of muscle damage.

Results Legs bone mass was significantly lower in patients than in controls (−36% for BMC and −22% for BMD). Moreover, patients had significantly higher LM values in the legs than controls, whereas no difference was found for fat mass. CK levels were positively associated with LM in McArdle patients. A correlation was found between LM and BMD variables in the control group but not in McArdle patients.

Conclusion We have identified a ‘non-osteogenic muscle hypertrophy’ in children with McArdle disease. This phenomenon warrants special attention since low osteogenesis at an early age predicts a high risk for osteoporosis later in life.

Introduction

McArdle disease (glycogen storage disease or ‘glycogenosis’ type V, myophosphorylase deficiency) is an inborn disorder of skeletal-muscle carbohydrate metabolism characterized by failure of muscle glycogen breakdown (Santalla et al. 2014a, b). Recent findings from the Spanish registry of McArdle patients (Santalla et al. 2017) show that the recognition of this disorder is increasing: 94 new patients (28% of total) have been diagnosed since the first report in January 2011 (Lucia et al. 2012). The majority of patients report symptoms or medical problems during the first decade of life, but are not usually correctly diagnosed until adulthood (Santalla et al. 2017). The occurrence of frequent, long delays in genetic diagnosis would suggest that many patients remain undiagnosed or are misdiagnosed (Santalla et al. 2017). United Kingdom centres have reported the same issue (Scalco et al. 2017).

Given the above, it is important to comprehensively describe the clinical phenotype of McArdle disease in children. This is especially relevant when considering that, until a curative treatment is eventually available, current epidemiological data support the early adoption of an active lifestyle as the best option for these patients, which can attenuate the deleterious...
consequences of the disease, notably fixed muscle weakness (Nogales-Gadea et al. 2016). We recently reported that physically inactive adult McArdle patients had lower lean mass (LM) values in whole-body and regional sites than their healthy age- and gender-matched peers, as measured by dual-energy X-ray absorptiometry (DXA) (Rodríguez-Gómez et al. 2018). Importantly, bone mineral content (BMC) and density (BMD) were also lower in patients than in controls, and as such we identified poor bone health as a previously undescribed condition in McArdle patients.

Early infancy is a critical period for skeletal development, during which enhancing bone accretion can help to reduce the risk of osteoporosis and bone fractures later in life (Golden and Abrams 2014; Mitchell et al. 2015). It was therefore the aim of our study to compare the body composition (including LM and BMC/BMD) of McArdle patients aged ≤16 years to that of healthy aged and gender-matched controls.

Materials and methods

Subjects and procedure

We followed a case-control, cross-sectional design. Patients (cases) were recruited for this study if they met the following criteria: (i) genetic diagnosis of McArdle disease, that is, identification of the two mutant alleles in the gene (PYGM) encoding myophosphorylase (Santalla et al. 2017); (ii) age ≤ 16 years; and (iii) having no condition contraindicating DXA (e.g., upcoming contrast tests). In total, 10 children with McArdle disease, five boys and five girls (13.8 ± 2.2 years), who met all the inclusion criteria were included in the study. Data were collected from 06/2015 until 06/2017. The parents/ tutors of age- and gender-matched healthy children (controls) with DXA data previously collected in our laboratory (see below) were contacted again and consented to have their children’s data used as historical controls for the present study. A total of 30 children, 15 boys and 15 girls (13.6 ± 2.2 years), were recruited to meet a patient-control ratio of ~1:3 from 2012 until 2017. During the same week of DXA assessment, anthropometric data (patients and controls) and serum creatine kinase (CK) levels (patients) were also assessed.

The study protocol was approved by the ethics committee of the Research Institute of the Hospital 12 de Octubre (Madrid, Spain; reference # 16/081) and adhered to the tenets of the Declaration of Helsinki 1961 (revision Edinburgh 2008). Signed informed consent was obtained from all participants, who were informed about the aims and procedures of the study, as well as of the possible risks and benefits.

Genetic diagnosis Mutant PYGM alleles were identified in patients’ muscle or blood samples as described elsewhere (Santalla et al. 2017). All the pathogenic PYGM mutations identified in our study patients are shown in the Supplementary file.

Anthropometry

Height and body mass were obtained for each subject using a calibrated balance and stadiometer (Seca 711, Hamburg, Germany), immediately before DXA assessment. Both measurements were performed in the upright position, and children wore only their underwear. Height was recorded in the Frankfort plane with a precision of 1 mm, and body mass was determined with 100 g precision. Body mass index (BMI) was calculated as body mass (kg) divided by height (m) squared (kg·m⁻²).

Body composition: lean, fat, and bone mass

Body composition and bone mass in whole-body and regional sites were assessed in all the study participants using the same DXA instrument (Hologic QDR Discovery, Bedford, MA), in the Laboratory of the GENUD Toledo Research Group of the University of Castilla-La Mancha (Toledo, Spain). The DXA instrument was calibrated daily against a lumbar spine phantom following the manufacturer’s guidelines. Physician’s View, APEX System Software Version 3.1.2. (Bedford, MA) was used to analyze all DXA scans. Scans were made with subjects in the supine position, wearing light clothing with no metal and no shoes or jewelry. LM (kg), fat mass (FM, kg), BMC (g), and BMD (in g·cm⁻²) were calculated from total and regional analysis of the whole-body scans. To determine the composition of the arms, legs, pelvis and trunk regions, whole-body scans were submitted to a regional analysis; in addition, lower-leg composition was determined by a specific sub-regional analysis. BMC and BMD were also reported for the proximal region of the femur (total hip, greater trochanter, inter-trochanter, Ward’s triangle and femoral neck). Full methodology has been described previously (Rodríguez-Gómez et al. 2018). The pediatric bone Z-scores were calculated in each participant for the whole-body and femoral neck.

Statistical analysis

Statistical analyses were performed with the IBM SPSS statistics package version 24 (SPSS, Inc., Chicago, IL). The Kolmogorov-Smirnov test and graphical methods (normal probability plots) were used to determine the normal distribution of the variables. The characteristics of the study groups were determined through basic descriptive tests. Differences in body composition variables between patients and controls were defined by Student’s t test and analysis of covariance (ANCOVA). Age, mass, height, age of symptom onset, and frequency of rhabdomyolysis episodes (as assessed by the number of reported episodes of myoglobinuria or ‘dark
Both groups were matched by age, body mass, height, and BMI. Anthropometric and descriptive data for the McArdle and control groups are shown in Table 1. The group of McArdle patients represent 26% of the total Spanish patient population of the same age (≤16 years) according to the recent update of patients (Santalla et al. 2017). Both groups were matched by age, body mass, height, and BMI.

Body composition

Between-group comparisons of total/regional LM and FM values, after controlling for the effect of age, body mass, height, age of symptoms onset, and frequency of rhabdomyolysis episodes, are shown in Table 2. LM in the lower extremities was significantly higher in patients than in controls (p < 0.05; Hedge’s g = 1.03 and 0.39; 9.9% and 28.6% of difference, legs and lower legs, respectively). There were no significant between-group differences in FM at whole-body and regional sites or in % body fat. Thus, the influence of body fat was similar for bone mass or LM, and this variable was excluded from subsequent analyses. Table 3 shows between-group comparisons of BMC and BMD after controlling for the effect of age, body mass, height, age of symptoms onset and frequency of rhabdomyolysis episodes. BMD in the lower legs was significantly lower in McArdle patients than in controls (p < 0.01; Hedge’s g = 1.26; 22% of difference). Whole-body and legs’ BMD showed near-significant differences, with small effect sizes (Hedge’s g = 0.39 in both cases; and 6.5 and 8.1%, p = 0.09 and p = 0.07, respectively). Medium effect size of the differences was found for the femoral neck (p > 0.05; Hedge’s g = 0.52 and 7.7% of difference) and small effect sizes were found for the pelvis, arms, trochanter, and Ward’s triangle (Hedge’s g from 0.30 to 0.44, from 3.2 to 10.1%). When comparing BMC, significant differences were found only in the lower legs (p < 0.01; Hedge’s g = 1.18; 35.8% of difference).

Association between whole-body and legs lean mass and bone mass and CK

The correlation coefficients between LM, BMD variables and CK are shown in Table 4. The main result was that CK was positively associated with whole-body and legs’ LM (p ≤ 0.01) in patients, but no significant associations were observed between LM and BMD. This latter finding was in contrast to that found in the control group.

Discussion

This study examined the differences in body composition between a representative sample of children with McArdle disease and age- and sex-matched controls. Our main, novel finding was that patients have significantly lower bone mass than their respective controls. By contrast, LM was similar between groups and was in fact higher in patients’ lower limbs.

Childhood and adolescence are crucial periods for the development of the skeleton. It is therefore important to achieve a high peak bone mass during these stages in order to prevent osteoporotic fractures later in life (Rizzoli et al. 2010). In this regard, the idea that ‘osteoporosis is a pediatric disease’ is increasingly accepted (Bachrach 2014; Marrani et al. 2017) and, in fact, prevention from childhood is the most powerful strategy against non-communicable diseases such as osteoporosis (Vicente-Rodríguez 2006). In the present study, BMC values of the McArdle children were, on average 6% lower and BMD values were, on average, 7% lower than those of their age- and gender-matched healthy peers. Moreover, the proportion of individuals with whole-body and femoral neck Z-scores indicative of osteoporosis and risk of bone fracture level was greater in the McArdle patient group than in the control group (i.e. 75% of the patients assessed here showed lower-than-normal bone mass values). Similar findings on bone mass have been recently reported by us in adult McArdle patients, who have compromised bone health (Rodriguez-Gómez et al. 2018), and in patients with other myopathies, such as glycogenosis type I (Schonau et al. 2002), Ia (children/adolescents) (Rake et al. 2003) and III (Melis et al. 2016; Rake et al. 2003; Schwahn et al. 2002), or Pompe disease (Bertoldo et al. 2015).
The finding of low BMD among children with McArdle disease despite their normal-to-high LM values might appear counterintuitive in light of the fact that high LM is probably the most important predictor for bone mass accrual during prepubertal growth in the overall population (Vicente-Rodríguez 2006). Such a muscle-bone relationship is presumably explained by the mechanostat theory, which posits that bone strength is regulated by modeling and remodeling processes that are dependent on the forces acting on the bones (Rauch et al. 2004; Schoenau and Frost 2002), with larger muscles usually exerting higher tensile forces on the bones they are attached to. Further, the result found here (high LM but low bone mass) appears to be specific to children and adolescents with McArdle disease, with adult patients showing rather low LM (unless they are active) as well as the 'normal', expected positive relation between whole-body LM and whole-body bone mass (Rodríguez-Gómez et al. 2018). As LM and BMD variables have not been previously reported together in patients with other types of glycosgenosis, we cannot infer whether the findings reported here are specific to children with McArdle disease (glycosgenosis type V) only.

Our findings suggest the existence of 'non-osteogenic muscle hypertrophy', in children and adolescents with McArdle disease. However, in the case of McArdle children, muscle hypertrophy is likely not associated with frequent exercise practice. Indeed, these children tend to refrain from practising sports activities that are typical for their age, especially in physical education classes or in the school playground (e.g., running, jumping) because these activities are the main trigger for symptom occurrence (Santalla et al. 2017). Yet, mechanical tensions induced by muscle contractions (i.e., the mechanostat theory) during such types of exercise are necessary to stimulate bone accretion (Eckhard Schoenau 2005). In children with McArdle disease, muscle hypertrophy could be the consequence, at least in part, of the ongoing muscle damage over life that characterizes this condition, as reflected by the high serum CK levels (a muscle damage marker) in our

### Table 2
Lean and fat mass composition from the total and regional body scans by group

<table>
<thead>
<tr>
<th>Lean mass (kg)</th>
<th>Fat mass (kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>McArdle (n = 10)</td>
<td>Control (n = 30)</td>
</tr>
<tr>
<td>Whole body</td>
<td>40.3 ± 1.3</td>
</tr>
<tr>
<td>Trunk</td>
<td>19.0 ± 0.8</td>
</tr>
<tr>
<td>Arms (mean)</td>
<td>2.0 ± 0.1</td>
</tr>
<tr>
<td>Legs (mean)</td>
<td>7.1 ± 0.3</td>
</tr>
<tr>
<td>Lower legs (mean)</td>
<td>0.7 ± 0.1</td>
</tr>
</tbody>
</table>

Data are mean ± SEM. * p < 0.05 for McArdle vs. control group (comparison results adjusted by age, body weight, height, age of symptom onset and frequency of rhabdomyolysis episodes)

### Table 3
Bone mineral content (BMC) and density (BMD) from the whole-body and femoral regions

<table>
<thead>
<tr>
<th>BMC (g)</th>
<th>BMD (g·cm⁻²)</th>
</tr>
</thead>
<tbody>
<tr>
<td>McArdle (n = 10)</td>
<td>Control (n = 30)</td>
</tr>
<tr>
<td>Whole scan</td>
<td></td>
</tr>
<tr>
<td>Whole body</td>
<td>1679.2 ± 87.0</td>
</tr>
<tr>
<td>Head</td>
<td>389.0 ± 19.2</td>
</tr>
<tr>
<td>Pelvis</td>
<td>188.8 ± 23.3</td>
</tr>
<tr>
<td>Arms (mean)</td>
<td>102.0 ± 6.1</td>
</tr>
<tr>
<td>Legs (mean)</td>
<td>316.6 ± 16.9</td>
</tr>
<tr>
<td>Lower legs (mean)</td>
<td>124.8 ± 18.8</td>
</tr>
</tbody>
</table>

Femoral regions

<table>
<thead>
<tr>
<th>BMC (g)</th>
<th>BMD (g·cm⁻²)</th>
</tr>
</thead>
<tbody>
<tr>
<td>McArdle (n = 10)</td>
<td>Control (n = 30)</td>
</tr>
<tr>
<td>Proximal femur (mean)</td>
<td>30.46 ± 2.03</td>
</tr>
<tr>
<td>Femoral neck</td>
<td>4.1 ± 0.3</td>
</tr>
<tr>
<td>Trochanter</td>
<td>5.3 ± 0.5</td>
</tr>
<tr>
<td>Intertrochanteric zone</td>
<td>21.2 ± 1.6</td>
</tr>
<tr>
<td>Ward’s triangle</td>
<td>0.8 ± 0.1</td>
</tr>
</tbody>
</table>

Data are mean ± SEM. ** p < 0.01 for McArdle vs. control group (comparison results adjusted by age, body weight, height, age of symptom onset, and frequency of rhabdomyolysis episodes)
patients (i.e., mean levels of ~4000 U/L, or 20-fold higher than the usual upper limits), which are in agreement with previous studies in children/adolescents with McArdle disease (García-Benítez et al. 2013; Perez et al. 2007).

Muscle damage is a major stimulus for muscle hypertrophy, with the subsequent skeletal muscle tissue inflammation and increased protein turnover being necessary for long-term hypertrophic adaptations to occur (Evans and Cannon 1991; Komulainen et al. 2000; Wernig et al. 1990). The reasons for the characteristic muscle damage, even at baseline, remain to be clearly elucidated. The mechanical stress imposed by high muscle glycogen stores, or the downregulation of Na\(^+\)–K\(^+\) pumps in patients’ muscles (with these pumps being responsible for maintaining cellular volume and integrity), are candidates to contribute, together with increase oxidative stress, to structural muscle fiber fragility and membrane disruption, leading to the efflux of intracytoplasmic proteins such as CK into the bloodstream (Santalla et al. 2014a, b). Most studies on healthy people show that CK levels correlate well with measures of muscle mass (Noori et al. 2011; Patel et al. 2013), and low CK levels are associated with low values of muscle mass (Oterdoom et al. 2009). On the other hand, the low values of LM mass recently reported by us in adult (mean age 33 ± 15 years) McArdle patients could be explained by the fact that the muscle damage-induced stimulus for muscle tissue hypertrophy does not compensate for the detrimental effects of lack of sports practice over decades.

Our study is not without limitations. We did not report nutritional data, and dietary factors, particularly calcium and vitamin D intake, are influential for bone mass acquisition (Smith et al. 2017). However, such dietary factors might not be determinant in childhood. For instance, vitamin D and calcium supplementation does not appear to affect bone mass in another pediatric condition, acute lymphoblastic leukemia (Demirsoy et al. 2017). Secondly, it would have also been useful to objectively assess physical activity levels in our participants; because physical activity and muscular development are major determinants of bone mass acquisition and low physical activity is associated with a reduced bone mass (Vicente-Rodríguez et al. 2005). Nonetheless, this is the first study to objectively assess body composition in McArdle children and adolescents using the gold standard DXA method, and we studied a representative sample of children. This is important when considering that only 5% of Spanish McArdle patients are correctly diagnosed during the first decade of life (Rodríguez-Gómez et al. 2018), and there is insufficient awareness and monitoring of this disease, especially among pediatricians (Alfredo Santalla et al. 2017).

In conclusion, we have identified a novel finding, non-osteogenic muscle hypertrophy, in children with McArdle disease. Thus, the recently identified problem of poor bone health in adult patients appears to start during childhood (Rodríguez-Gómez et al. 2018). Future research might determine if specific dietary interventions (e.g., calcium supplement intake) and/or structured exercise can attenuate this problem in this period of life, and which exercise modality would be more appropriate for children with this characteristic to maximize bone mass accretion.

**Acknowledgments** This study was funded by the Cátedra Real Madrid - Universidad Europea de Madrid (P2016/RM25), Fondo de Investigaciones Sanitarias (A.L., P115/00558; G.N.G, P115/01756 and CP14/00032, J.A., P114/00930), AFM Telethon Trampoline Grant #21108, the Biomedical Research Networking Center on Frailty and Healthy Aging (CIBERFES) and FEDER funds from the European Union (CB16/10/00477). Irene Rodríguez Gómez has received a PhD grant from the Universidad de Castilla-La Mancha “Contratos predoctorales para la formación de personal investigador en el marco del Plan Propio de I+D+i, cofinanciados por el Fondo Social Europeo” (2014/10340).
Compliance with ethical standards

Conflict of interest None.

References